Hacking pancreatic cancer: Present and future of personalized medicine
| Autor: | Valentina Tateo, Mariacristina Di Marco, Andrea Palloni, Giorgio Frega, Dalia Ricci, Riccardo Carloni, Giovanni Brandi, Alessandro Rizzo, Alessandro Federico, Francesca Formica, Claudia Parisi |
|---|---|
| Přispěvatelé: | Di Federico A., Tateo V., Parisi C., Formica F., Carloni R., Frega G., Rizzo A., Ricci D., Di Marco M., Palloni A., Brandi G. |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty medicine.medical_treatment Population Pharmaceutical Science Tyrosine kinase inhibitor Review Olaparib Targeted therapy 03 medical and health sciences chemistry.chemical_compound Pharmacy and materia medica 0302 clinical medicine Internal medicine Pancreatic cancer Drug Discovery Medicine education PARP inhibitors Tumor microenvironment education.field_of_study business.industry Cancer Immunotherapy medicine.disease Personalized medicine RS1-441 030104 developmental biology Metabolism PARP inhibitor chemistry 030220 oncology & carcinogenesis Genomic Molecular Medicine DNA damage business |
| Zdroj: | Pharmaceuticals Pharmaceuticals, Vol 14, Iss 677, p 677 (2021) |
| Popis: | Pancreatic cancer (PC) is a recalcitrant disease characterized by high incidence and poor prognosis. The extremely complex genomic landscape of PC has a deep influence on cultivating a tumor microenvironment, resulting in the promotion of tumor growth, drug resistance, and immune escape mechanisms. Despite outstanding progress in personalized medicine achieved for many types of cancer, chemotherapy still represents the mainstay of treatment for PC. Olaparib was the first agent to demonstrate a significant benefit in a biomarker-selected population, opening the doors for a personalized approach. Despite the failure of a large number of studies testing targeted agents or immunotherapy to demonstrate benefits over standard chemotherapy regimens, some interesting agents, alone or in combination with other drugs, have achieved promising results. A wide spectrum of therapeutic strategies, including immune-checkpoint inhibitors tyrosine kinase inhibitors and agents targeting metabolic pathways or the tumor microenvironment, is currently under investigation. In this review, we aim to provide a comprehensive overview of the current landscape and future directions of personalized medicine for patients affected by PC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|